Member Info for 1pencil

Good point, I would need to look at previous takeovers/precedents being set , however someone like Astra has roots in China going back to the 90's.

Hutchmed is also medial so not really anything sensitive.

What a fantastic finish for the initial Rule 8 notifications, couldn't ask for more with two (one ex) partners at Balderton buying on the own account, not peanuts either, 4% what a huge vote of confidence in management.

I have tried to include everyone but please update if there's any missing.

Day 10

Long positions, previous notified holdings in (brackets)

Ophorst Van Marwijk Kooy Asset Management (1.94%) ……………………… 1.93%

Balderton Capital (UK) LLP ……………………… 7.46%

BlackRock, Inc (1.23%) ……………………… 1.22%

The Vanguard Group, Inc. (2.62%) ……………………… 2.63%

Sofina Capital S.A ……………………… 8.89%

Kelso ……………………… 0.60%

Brian George Kennedy ……………………… 2.86%

Norges Bank (1.72%) ……………………… 1.73%

West Coast Capital (1.41%) ……………………… 2.03%

Qatar Investment Authority ……………………… 7.32%

Matthew Moulding/Close relative of Matthew Moulding ……………………… 15.80%

THG Employee Benefit Trust ……………………… 5.90%

Tim Bunting (Balderton Capital (UK) LLP) ……………………… 1.31%

Mark Evans (ex- General Partner at Balderton) ……………………… 2.71%

Sir Terence Patrick Leahy ……………………… 1.24%

HARBROOK LIMITED ……………………… 1.97%

Total ……………………… 65.60%

Notifications deemed trading or prop accounts omitted

Some director buying might help change sentiment.

Those are my sentiments too (see earlier post) PHC may as well list where there is investor interest, or merge be bought out - paying £250-350k a year just to flatline on AIM isn't good value imo, this mornings response is a prime example, huge drop on positive news, little investor interest to support it.

Two other companies which I have invested have similar issues, one a biotech (HCM) has signed $1b plus deal with $400m cash upfront, stock sits at a near 10 year low. THG dropped to ridiculous levels way beyond anything normal, its now received a bid approach from Apollo.

PHC current valuation is less than half the amount spent on PREtec

This mornings communication is obviously from the board but those driving it are likely to be shareholders themselves, Griffiths needs a return on his investment here. Some of the earlier fund raisings were well over 100p having touched 400p at one stage.

Its very likely this is a softening up prior to going private, Griffiths will have to sign it off so there is that level of protection as his average price will be a lot higher than where we are now.

So Balderton and & Co own over 10%, no need for any Golden share that was just media guff ..

Followed Mark Kleinman for sometime, he is the real deal - good spot blert..

..crumbs for a CEO that has no support ..he sure has a lot of support...

Agree bots, James Ede-Golightly is also Griffiths right hand man, often gets appointed to boards to help steer the ship.

London market is a bit of a backwater for growth companies hence the exit by many aspiring companies, highly likely the board have already had discussions with the like of Wilbur-Ellis and others, Ospraie is another option to go private.

https://ukinvestormagazine.co.uk/plant-health-care-be-an-opportunist-and-jump-aboard-now-after-the-25-share-price-fall/

Not sure why the drop in price, surely this is good news for holder with the board exploring options on how to increase shareholder value/share price?

Strong results make this a very attractive PE target imo, Griffiths will want maximum return for UK investors given his epic investment over the years - mopped up overhang

Trying to buy very difficult, had to drop down to 50k bites

This looks like a run up to being sold off, could be wrong but lots of stored value here - lets see how Scobie/ Ospraie AG/Grifiths respond

All it needs is to be bought by a company domiciled outside of China, after all no one bats an eyelid at Apple or Tesla, both of which have huge operations in Shanghai.

HK register, none of the larger holders appear to have sold, last entry is Jan 23 where M & G increased their holding after some previous disposals.

Couldn't see any entries for major shareholders in this years 2022 AR, only directors interests/Hutchison Healthcare

All Executive Officers and Directors as a Group 2.2%
Hutchison Healthcare Holdings Limited 38.5 %

As investors we kick ourselves when stocks drop and we don't buy, well here we are at 250p trading at a substantial discount to the last fund raising in 20221:

"The Company entered into cornerstone investment agreements with investors affiliated with The Carlyle Group, Canada Pension Plan Investment Board, General Atlantic, HBM Healthcare Investments and CICC Grandeur Fund. Pursuant to such agreements, they subscribed for a total of 63,215,500 Offer Shares, representing approximately 61% of the Offer Shares offered under the Global Offering (assuming the over-allotment option is not exercised)."

"As announced on June 23, 2021, the final offer price for both the International Offering and the Hong Kong Public Offering (the "Offer Price") was set at HK$40.10 per Share, which is equivalent to approximately US$25.82 per American depositary share ("ADS") or £3.70 per Share. Each ADS represents five ordinary shares of the Company."

On top of that we have the Takeda deal being signed removing future cash flow issues, HFCAA is done and dusted so one could argue Hutchmed is at the least risk since inception..

There's another Mail article on the rise of beauty companies and how THG has been left behind, lots of press coverage drawing attention to the chronic under valuation.

The board must be coming to the same conclusion as the rest of us, namely that a full market valuation is not possible whilst US/China tensions persist, short sellers know this and will take full advantage.

Share price isn't much above pre- HFCAA now that that's resolved those pulling the strings find something else..

Price wise, anyone's guess- I tend to start with baseline figures, the first being last fund raise and go from there, perhaps somewhere around £4.60 - 5.00p mark would suffice.

You also have to pose the question, 'what is the point of being listed' ? HCM no longer need to raise funds from the capital markets, being listed on three exchanges is hugely expensive and time consuming for management.

Hutchmed has a much greater prospect of achieving its aims under the wing of Astra or Takeda, both of which have strong aspirations for China but are domiciled elsewhere..

I don't see CK Hutchison Holdings (CKHH) as being that much of an obstacle as they too would be aware of the current political tensions which persist.

Gone by year end or sooner would be my call, for all the reasons listed here its just too cheap - Astra have voiced their intentions very clearly but don't rule out Takeda, both contenders imo

Imagine announcing a five-year deal in a bull market, not even a mention these days.

o Celio: 5-year partnership to support major French retailer with D2C replatform in India.

Plus you have the whole GOAT thing in India too, largest market by populous in the world, overtaking China.

o G.O.A.T Brand Labs: Strategic partnership to build and execute localised digital capabilities in India, in addition to replatforming a selection of brands in India home market with internationalisation to follow.

https://www.celio.in/

Yup, Tuesday -

Hosai, makes sense but there are implications on price setting for bidders buying ahead of actual bid, forgotten exactly and tad complex (and boring lol)

Not much change here but once again encouraged by lack of rejection as it were, I find it hard to believe both parties would let this continue without some substance, market appears to agree..

One other note on the rule 8 notifications, next week is the deadline but only for existing holders to notify, we will still have these right up until end of the bid process, which may or may not be extended with board approval.

Of course its relevant, 4th largest shareholder recently adding.

Ospraie AG Science have the lions share so big holders and which way they would vote is an important factor should corporate action emerge.

There's a huge amount of M & A at the moment on London markets, PHC is trading well below its intrinsic value so any possible stake building should be considered important imo.